PALO ALTO, CA, Feb. 14, 2012 /CNW/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced that Dr. George F. Tidmarsh, MD, PhD, Executive
Director, is scheduled to present a corporate update at the BIO CEO &
Investor Conference in New York. Dr. Tidmarsh's presentation will be
webcast live and takes place on Tuesday, February 14, 2012, at 3:30
p.m. ET at the Waldorf-Astoria Hotel in New York City.
Dr. Tidmarsh plans to provide an update on the company's corporate
strategy and progress in the clinical development of ANAVEX 2-73 for
the treatment of Alzheimer's Disease (AD), which has successfully
completed a Phase 1a clinical trial. Data published by world-renowned
Alzheimer's Disease scientists shows that ANAVEZ 2-73 exhibits
neuroprotective activity and reverses symptoms of AD in mouse models of
the disease. Phase 1a clinical data indicates that ANAVEX 2-73 is well
tolerated with no dose-limiting toxicities unrelated to the drug's
mechanism of action. ANAVEX 2-73 is the first of a new class of oral
drugs being studied to potentially treat Alzheimer's through disease
modification rather than symptomatic improvement alone.
The Anavex presentation will be webcast live at: http://www.veracast.com/webcasts/bio/ceoinvestor2012/36215125.cfm. Please register and log in approximately 10 minutes prior to the
presentation to ensure a timely connection. The webcast replay will be
available one hour after conclusion of the presentation and will be
archived until May 14, 2012.
The BIO CEO & Investor Conference is the largest investor conference
focused on established and emerging publicly traded biotech companies.
About Alzheimer's Disease
While Alzheimer's Disease is most common in people over the age of 65,
it can strike adults of any age irrespective of their gender,
background or socioeconomic status. According to the Alzheimer's
Association, an estimated 5.4 million Americans are currently living
with Alzheimer's disease. The number of Americans aged 65 and over with
Alzheimer's is estimated to reach 7.7 million in 2030. This represents
a 50 percent increase from the 5.2 million Americans aged 65 and older
who are currently affected. The Alzheimer's Association further
projects that the number of Americans aged 65 and older who are
affected by Alzheimer's disease may double or triple to between 11 and
16 million by 2050 unless there are developments to prevent or more
effectively treat the disease.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and
development of novel drug candidates for the treatment of neurological
diseases and cancer. The Anavex proprietary SIGMACEPTOR™ Discovery
Platform involves the rational design of drug compounds targeted to
specific receptors involved in the modulation of multiple cellular
biochemical signaling pathways.
The SIGMACEPTOR™-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer's disease, epilepsy, depression, pain). The company's lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties. A
portfolio of back-up compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
SOURCE Anavex Life Sciences Corp.
For further information:
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092